Skip to Main Content

A uterine fibroid treatment from Myovant Sciences met its goals in a second late-stage trial, setting the stage for Food and Drug Administration approval and competition with a pharmaceutical giant.

The drug, relugolix, significantly reduced menstrual blood loss, the most common symptom of uterine fibroids, and beat placebo on six other metrics including pain and quality of life, according to data released Tuesday. About 71% of women who took the daily pill responded to the therapy, experiencing at least a 50% reduction in blood loss over 24 weeks and falling below the FDA’s definition of heavy menstrual bleeding. The drug’s safety profile was similar to that of placebo, including on the key metric of bone density.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!